More than 8,000 patients with elevated Lp(a) and established cardiovascular disease took part in this study. Although the drug, pelacarsen, successfully lowered their Lp(a) levels, this did not translate into fewer cardiovascular deaths, heart attacks, strokes, or urgent procedures to restore blood flow to the heart.
The result is particularly interesting in light of research published over three decades ago by Dr. Matthias Rath and two-time Nobel laureate Dr. Linus Pauling. They proposed that Lp(a) acts as a biological substitute, or surrogate, for vitamin C in humans and other species unable to produce the nutrient themselves, and suggested there was an inverse relationship between levels of the two substances. Animal experiments showed that adequate amounts of vitamin C prevented the accumulation of Lp(a) in arterial walls.
The failure of pelacarsen illustrates why pharmacologically lowering a cardiovascular risk marker should not automatically be assumed to improve patients’ health. Rather than simply suppressing individual risk factors, Dr. Rath’s Cellular Medicine approach seeks to address the underlying nutritional processes involved in maintaining the strength and stability of blood vessel walls. More than three decades after his research was first published, the failure of Novartis’ drug provides still further reason for conventional medicine to examine the Cellular Medicine approach more seriously.
To read more about Dr. Rath’s discovery that there is an inverse relationship between levels of vitamin C and the body’s production of Lp(a), see this article on our website.
Popular GLP-1 Weight-Loss Drugs May Trigger Rare Life-Threatening Brain Disorder
September 18, 2026Scheduled for Surgery? Studies Show Your Vitamin Levels May Matter More Than Doctors Realize
September 18, 2026Novartis Lp(a) Drug Fails to Lower Cardiovascular Risk
News
A Novartis drug designed to lower levels of Lp(a), a known cardiovascular risk factor, failed to reduce patients’ risk of a heart attack, stroke, or other major cardiovascular events in the first late-stage test for a drug meant to tackle the mysterious molecule.
[Source: fiercebiotech.com]
[Image source: unsplash.com]
Comment
More than 8,000 patients with elevated Lp(a) and established cardiovascular disease took part in this study. Although the drug, pelacarsen, successfully lowered their Lp(a) levels, this did not translate into fewer cardiovascular deaths, heart attacks, strokes, or urgent procedures to restore blood flow to the heart.
The result is particularly interesting in light of research published over three decades ago by Dr. Matthias Rath and two-time Nobel laureate Dr. Linus Pauling. They proposed that Lp(a) acts as a biological substitute, or surrogate, for vitamin C in humans and other species unable to produce the nutrient themselves, and suggested there was an inverse relationship between levels of the two substances. Animal experiments showed that adequate amounts of vitamin C prevented the accumulation of Lp(a) in arterial walls.
The failure of pelacarsen illustrates why pharmacologically lowering a cardiovascular risk marker should not automatically be assumed to improve patients’ health. Rather than simply suppressing individual risk factors, Dr. Rath’s Cellular Medicine approach seeks to address the underlying nutritional processes involved in maintaining the strength and stability of blood vessel walls. More than three decades after his research was first published, the failure of Novartis’ drug provides still further reason for conventional medicine to examine the Cellular Medicine approach more seriously.
To read more about Dr. Rath’s discovery that there is an inverse relationship between levels of vitamin C and the body’s production of Lp(a), see this article on our website.
Dr. Rath Health Foundation
Related posts
Swiss Football Captain Under Investigation Over Forged COVID-19 Vaccination Certificate
Read more